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Abstract
Mefenamic acid as pain relief drug belongs to the biopharmaceutics classification system (BCS) class II which is practically insoluble
in water causing extremely low dissolution in gastrointestinal tract. The selfnanoemulsifying drug delivery system (SNEDDS) is
a new innovation pharmaceutical dosage form that has effectively known to increase solubilization of hydrophobic drug in polar
solvent. In this study the capryol-90 was selected as oil phase in SNEDDS as it showed maximal solubility of mefenamic acid (20
mg/mL). Combination of polysorbate-80 and PEG-400 as a generally regarded as safe (GRAS) excipient were used as surfactant
and co-surfactant in SNEDDS due to its high HLB property that can increase mefenamic acid solubility in water. The ternary phase
diagram of capryol-90, polysorbate-80, and PEG-400 was constructed in advance to obtain the component concentration of
spontaneous nanoemulsion region. Model simplex-lattice-design cooperated in Design-Expert® was used to define SNEDDS
mefenamic acid formula. Optimized mefenamic acid SNEDDS formula consisted of 20% capryol-90, 31.62% polysorbate-80, and
48.38% PEG-400. Characterization study of Optimized mefenamic acid SNEDDS formula showed improvement of drug content
(102.820 ± 4.950)%, emulsification time (421.015 ± 1.290) second, and viscosity (0.927 ± 0.017) mm2/s 30°C. One way ANOVA
statistical analysis result of optimal formula SNEDDS (105.210 ± 4.425)% of drug content, commercial generic caplet (0.917 ±
0.094)%, and mefenamic acid powder capsule (10.446 ± 0,333)% gave significant value (sig*) below than 0.05. Optimal formula
proved that SNEDDS can significantly increasemefenamic acid dissolution of pH 7.4 (ileum fluid). The optimal formula of mefenamic
acid SNEDDS successfully formed an uniformity droplet size (PDI 0.18) with mean size 241.9 nm and the surface charge has a value
of -16.5 mV respectively.
Keywords
Mefenamic acid, SNEDDS, Capryol-90, Polysorbate-80, PEG-400
Received: 1 September 2018, Accepted: 30 September 2018
https://doi.org/10.26554/sti.2018.3.4.164-172
1. INTRODUCTION
Mefenamic acid as antiinammatory non steroid (AINS) drug is
used for analgesic to relief headache, toothache, dysmenorrhea,
rheumatoid arthritis, osteoarthritis, muscle pain, traumatic and
post operation (Mudalip et al., 2013). Mefenamic acid already
known asthe most traded drug in middle-income countries and
in high-income countries. This achievement shows the level of
its consumption occurring in the community (McGettigan and
Henry, 2013). High oral dosage of commercial mefenamic
acid (500 mg) can increase the probability of side eect such
as cardiovascular thrombosis, stroke, congestive heart failure,
udem, ulceration, bleeding, and gastrointestinal perforation.
This concern caused by the low solubility of mefenamic acid in
instestinal uid (BCS Class II), therefore it has poor bioavail-
ability and absorption. Based on its properties, FDA (2008)
recommends the use of mefenamic acid the lowest eective
dose (Mudalip et al., 2013).
Nanosized particles (± 200 nm) of drug has been shown
to improve the absorption of drugs so the usage dose can be
reduce without decreasing the ecacy (Mardiyanto, 2013; Yoo
et al., 2010). The self nano emulsifying drug delivery sys-
tem (SNEDDS) is one of the nanoparticles dosage form which
can increase drug solubility and maximize the absorption in
gastrointestinal tract by emulsication mechanism (N.A et al.,
2017; Sutradhar and Amin, 2013). The succeed level of emul-
sication is quite high because of the spontaneous emulsion
forming of oil in water (o/w) only need weak agitation (Gursoy
and Benita, 2004).
The SNEDDS composition used in this study are capryol-
90 as dispersed phase, polysorbate-80 as surfactant, and PEG-
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400 as co-surfactant. The hydrocarbon chain of Capryol-90
can dissolve the lipophilic drug better and make it not eas-
ily oxidized(Anton and Vandamme, 2009). The high HLB
(hydrophilic lipophilic balance) of polysorbate-80 (15.0) can
increase the hydrophilicity, dissolution, and diusion of mefe-
namic acid in gastrointestinal tract so that the absorption pro-
cess can be more eective (Chen et al., 2018; Shahba et al.,
2012). PEG-400 is used for reducing the amount of polysorbate-
80 usage to maintain nanoemulsion droplet size does not to
be large, hence the paracellular diusion and dissolution can
increase (Sriamornsak et al., 2015).
Software Design Expert® Version 10 (DX®10) is used for
minimazing the trial of SNEDDS optimized formula study
which has the best droplet size and dissolution. Simplex lattice
design (SLD) is chosen as the appropriate optimization model
for 3 component formulation. SLD model is very appropriate
for this study because it can calculate the response value of
experiment total to the eect of dierences in the amount of
material on each formula (Armstrong, 2006). This study is
expected to determine the optimized formula of SNEDDS
mefenamic acid that can improve the absorption of mefenamic
acid.
2. EXPERIMENTAL SECTION
2.1 Materials
The materials which used in this study were mefenamic acid
(DexaMedica), capryol (TM90 typeNF) (Gattefosse), polysorbate-
80 (Gattefosse), PEG-400 (Gattefosse), ethanol p.a (Merck®),
NaOHp.a. (Merck®), KH2PO4 (Pzer®), methanol p.a. (Merck®),
anhydrous CH3COOH (APS), anhydrous CH3COONa (Merck®),
and aquabidest (IPHA Laboratories).
2.2 Methods
2.3 Determination Mefenamic Acid Solubility in Capryol-
90
The solubility test was performed by dissolving mefenamic acid
(2.4; 2.6; 3.4; 10; dan 20 mg) in 0.5 mL capryol-90 in a vial.
The mixture was then stirred with a magnetic strirrer in 150
rpm for 15 minutes and then sonicated (bath-sonicator Covaris
S220) for 45 minutes. Formation of the precipitate at each
mixture was observed to determine the maximum solubility of
mefenamic acid in capryol-90 (Sriamornsak et al., 2015).
2.4 Ternary Phase Diagram Construction
Capryol-90 (0-100% v/v), PEG-400 (0-100% v/v), and polysorbate-
80 (0-100% v/v) as continues oil phase, surfactan, and co-
surfactan were combined into 21 ternary phase. Mixture of
capryol-90, PEG-400, and polysorbate-80 were stirred (IKA-
47) with magnetic stirrer 300 rpm at room temperature for 15
minutes (Taha et al., 2004).
2.5 Self-emulsication and PrecipitationTernary PhaseDi-
agram Study
Self-emulsication of 21 ternary phase was studied by slowly
dropping of 80 µL ternary phase solution into 50 mL aquadest
in Beaker glass (1:625) while stirring on magnetic stirrer 100
rpm. Self-emulsication ability of 21 ternary phases were as-
sessed after all components were dispersed homogeneously
through the color, clarity, and the presence of globules in emul-
sion. Precipitation parameter, such as clarity, separation phase,
and the presence of precipitation or globule were observed
after 24 hours self-emulsication study with light observation
(Craig, 1995).
2.6 Ratio Component SNEDDS Mefenamic Acid
Composition ratio of capryol-90, polysorbate-80, and PEG-
400 was determined using simplex lattice design method soft-
ware DX®10. The sum of three components was 1 with low
value 0 while high value was 1 (Table 1). It was replicated
3 times so the selected model was quadratic. There were 3
responses result that was entered in DX®10 to determine op-
timized formula; drug content, emulsication timefor 13 for-
mulas.
Table 1. Proportion of capryol-90; polysorbate-80; PEG-400
Level
Proportion (%)
Capryol-90 Polysorbate-80 PEG-400
Low 20 20 40
High 40 40 60
2.7 SNEDDS Mefenamic Acid Preparation
Mefenamic Acid SNEDDS (Table 2) was prepared by dissolv-
ing mefenamic acid in capryol-90 on magnetic stirrer 150
rpm, then it was sonicated for 45 minutes at room temperature.
PEG-400 was added and the mixture was resonicated for 45
minutes. At the last, polysorbate-80 was added and the mix-
ture using bath sonicator for 10 minutes to obtain the yellowish
solution.
2.8 SNEDDS Characterization
2.8.1 Drug Content
Mefenac acid SNEDDS of 10 µLwas diluted in 5mLmetanol
p.a then the absorbance was measured by spectrophotometer
(Fischer Scientic evolution-201/220)UV-Vis in λmax 285
nm (Yadav et al., 2014). The process was replicated in three
times.
2.8.2 Emulsication Time and Precipitation
Emulsication time was observed at room temperature. SNEDDS
of 20 µL was diluted in 12.5 mL aquadest with magnetic stir-
rer 150 rpm until SNEDDS (clear solution or milky without
globul of oil) was formed. Precipitation using centrifuge (Lab-
DS 1001SD)parameter; such as clarity and phase stability after
24 hours, was observed under the light (24 hours start from
the last stirred) (Craig, 1995; Pouton, 1997).
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Table 2. Formula SNEDDS Mefenamic Acid
Formula Mef Ac (mg) Capryol (mL) Polysornat80 (mL) PEG-400 (mL)
Run 1 40 20,00 40,00 40,00
Run 2 40 30,00 30,00 40,00
Run 3 40 40,00 20,00 40,00
Run 4 40 23,33 33,33 43,33
Run 5 40 20,00 40,00 40,00
Run 6 40 20,00 30,00 50,00
Run 7 40 30,00 20,00 50,00
Run 8 40 23,33 23,33 53,33
Run 9 40 20,00 20,00 60,00
Run 10 40 20,00 20,00 60,00
Run 11 40 40,00 20,00 40,00
Run 12 40 26,67 26,67 26,67
Run 13 40 33,33 23,33 43,33
2.8.3 Formula Optimization
SNEDDS component of 13 formulas was optimized using
SLD method in DX®10was based on the result of 3 responses
with specic criteria arrangement. Combination of SNEDDS
component that had the highest desirability in solution was
chosen as optimized formula.
2.8.4 Study Response SNEDDS Mefenamic Acid
Response test point was re-studied to 3 batches of the SNEDDS
optimized formula (Table 2) along with in vitro dissolution
study, diametermeasurement, PDI, and zeta potential of SNEDDS
globules. Drug content measurement of the nal physical sta-
bility sample was evaluated furthermore.
2.8.5 In Vitro Dissolution
Dissolution study using dissolution equipment (Pharmatest
ptsw-D62) of SNEDDS, capsule, and generic caplet of mefe-
namic acid were studied in triplo. Transparent hard-capsule
of number 0 (0.82 mL) was lled with 0.6 mL SNEDDS of
optimized formula while capsule number 0 (1,2 mL ≈ 600 mg)
was lled with 500 mg pure mefenamic acid. Capsule contain
SNEDDS, pure mefenamic acid, and generic caplet were put
into 500 mL buered SIF pH 7.4 at 37 ± 3°C with rotation
speed 100 rpm for 60 minutes. Aliquot (5 mL) was taken in
minutes of 0; 5;10; 15; 20; 25; 30; 35; 40; 50 and 60. Caplet
and Capsule pure drug aliquot was ltered using Whatmann
lter 0.22 µm. Aliquot absorbance was measured with spec-
trophotometer UV-Vis in λmax 285 nm (Sriamornsak et al.,
2015).
2.8.6 Diameter, PDI, and Zeta Potensial SNEDDS Glob-
ules
SNEDDS mefenamic acid 500 µL was dropped into 5 mL
aquabidest (emulsion 1:10) on a magnnetic stirrer 150 rpm,
then stirred for 1 hour. Emulsion of 5 mL was poured into
microcuvette of particles size analyzer (Horiba-SZ100) to mea-
sure the size, PDI, and zeta potential SNEDDS droplet (Mardiyanto,
2013).
2.9 Statistic Analysis
2.9.1 Optimized Formula
Dierences bipolysorbate result study of drug content, and
emulsication time of SNEDDS optimized formula andDX®10
prediction was analyzed using one sample t-test method in
Minitab 17 Statistical® software. Analysis result was indicated
to be signicantly dierent if p-value< 0.05.
2.9.2 In Vitro Dissolution Study
% Release and DE60 dierences bipolysorbate SNEDDS cap-
sule, pure drug capsule, and generic caplet was analyzed using
one-way ANOVA method in software SPSS®20. Comparison
post hoc result of each group can be seen from Tukey dan LSD
report. Analysis result wasindicated to be signicantly dierent
if sig value <0.05.
3. RESULTS AND DISCUSSION
3.1 Determination ofMefenamicAcid Solubility inCapryol-
90
Themaximum solubility ofmefenamic acid in oil phase (capryol-
90), surfactant (polysorbate-80), and co-surfactant (PEG-400)
were used as the basis for determination the amount of mefe-
namic acid that can be added in the SNEDDS formula. The
Phase plays important role to maintain active drugs and re-
main in dissolved state in emulsion, therefore It was important
to know the solubility of mefenamic acid in capryol-90 (Sri-
amornsak et al., 2015). Based on the former study result,
capryol-90 was the best oil phase to dissolve mefenamic acid
(20 mg/mL) compared with clove oil (9.95 mg/mL) (based on
study conducted by Sriamornsak et al. (2015). It was caused by
the natural surfactant properties of capryol-90 medium chain
that can dissolve more hydrophobic substances (Constantinides,
1995; Karim et al., 1994).
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3.2 Selection of SNEDDS Mefenamic Acid Component
Selection of oil phase, surfactant, and co-surfactant become
critical point to increase the active drug solubility and drug load-
ing in self emulsifying dosage form. Selected components were
preferable having maximum solubility.Miscibility towards all
components that contained in the dosage form was to produce
a stable formula. Capryol-90 was chosen as oil phase because
it had solubility ± 2 times than clove oil. Amphiphilic nature of
hydroxy group capryol-90 had natural surfactant characteristic.
This benet can reduce the amount of surfactant used so it also
can minimize the toxicity risk as result of high concentration
use of surfactant (Jaiswal et al., 2014).
Besides that, clove oil can irritate the mucus membrane,
so capryol-90 nally was chosen (Sriamornsak et al., 2015).
Another benet of using capryol-90 as oil phase is its biodegrad-
able properties and ability to form nanoemulsion. Polysorbate-
80 is chosen as surfactant because it has high HLB (15.0) so
it can dissolve mefenamic acid eciently. Polysorbate-80 is
safe for human consumption because its non-ionic characteris-
tic has low toxicity. Besides that, hidrophilic characteristic of
polysorbate-80 is very appropriate with watery condition of
gastric and intestine that hadmuch hydrophilic uid (Sriamorn-
sak et al., 2015). Although polysorbate-80 (31.94 mg/mL)
has lower solubility than polysorbate-20 (36.96 mg/mL) (Sri-
amornsak et al., 2015) but polysorbate-80 is more selected
than polysorbate-20 according to the result study of lornoxi-
cam SNEDDS shows that the need of Smix (surfactant and
cosurfactant) toform capryol-90 into emulsion is reduced by
the use of polysorbate-80 as surfactant than polysorbate-20.
This result showed that the ability of polysorbate-80 to form
capryol-90 into emulsion state was greater than polysorbate-
20.
Combination of polysorbate-80-capryol-90, polysorbate-
80-transcutol and polysorbate-80-PEG-400 is categorized as
GRAS (generally regarded as safe) (FDA LLWL 1349) (Jaiswal
et al., 2014). The reason to choose PEG-400 (29.79 mg/mL)
than Transcutol® HP (38.76 mg/mL) (Sriamornsak et al.,
2015) was based on SNEDDS hydrochlortiazid study by Ya-
dav et al. (2014) that showed the necessary amount of surfac-
tant to expand the nanoemulsion region in Smix of PEG-400
and polysorbate-80 was less than using Smix transcutol and
polysorbate-80. Using polysor-bate 80 in high concentration
can make the size of globul bigger, therefore PEG-400 was
chosen as co-surfactant SNEDDS. Based on this data, capryol-
90, polysorbate-80, and PEG-400 were chosen as component
SNEDDS mefenamic acid to be studied furthermore.
3.3 Determination Nanoemulsion and Ternary Phase Dia-
gram of mefenamic acid SNEDDS
Proportion of capryol-90, polysorbate-80, and PEG-400 that
able to form spontaneous nanoemulsion was determined by
preparationof 21 combination of ternary phase diagram. Abil-
ity of forming nanoemulsion spontaneously was assessed after
aquadest was added drop by drop into ternary phase solution.
This assessment was designed like that because emulsion will
only be formed if one of the emulsion phases had dispersed
into small droplet form.
Nanoemulsion of ternary phase has just formed sponta-
neously (blue and green circle) in Figure 1 if minimal pro-
portion of polysorbate-80 is 20%. The increase proportion of
polysorbate-80 and PEG-400 can make the emulsion more
clear or transparent because of the adsorption surfactant and
co-surfactant on oil and water surface reduce the tension sur-
face energy and cohesion force in emulsion system so emulsion
became more stable (Sriamornsak et al., 2015). SNEDDS so-
lution become clear because nanoemulsion globul was < 100
nm, meanwhile the turbid SNEDDS was formed because the
globule size is > 10 µm (Porter et al., 2007).
The increase of capryol-90 proportion caused oil globules
can not be dispersed but coalesced on the surface. This was
happened because HLB polysorbate-80 and PEG-400 didn’t
comply with the HLB requirement. As the result, polar and
non polar group of polysorbate-80 and PEG-400 as capryol-
90 and aquadest as illustrated in Figure 3, the joint was not
available enough. This aects the stability of dispersion system
and then the unstable emulsion was formed (Azeem et al.,
2009).
Component proportion that form nanoemulsion region
in 13 SNEDDS formulas determination (Table 2) was re-
arranged in order to comply the total component of optimized
SLDmodel into 100% so the software showed the combination
proportion of nanoemulsion component which then will be
studied.
Precipitation was observed to investigate the risk of precip-
itation of capryol-90 after dispersed in water (Mohsin et al.,
2009). Precipitation of capryol-90 aects the reduction of the
absorbed mefenamic acid amount. 21 ternary phase stability
show that at least there is 80% ternary phase component in
dissolve state during 24 hours (Shahba et al., 2012).
3.4 Visual Observation of SNEDDS Mefenamic Acid
Formulas SNEDDS of 13 and optimized formula produced
slightly viscous yellow transparent solution without precipita-
tion with slightly coconut odor (Figure 2). The yellow color
of SNEDDS became intense with increasing the amount of
polysorbate-80 because polysorbate-80 had concentrated yel-
low color (Rowe et al., 2009).
3.5 Drug Content Measurement
Drug content was measured to know the mefenamic acid con-
centration in SNEDDS. This data was used to determine the
usage dose (Tzafriri et al., 2012). Methanol was chosen as
SNEDDS solvent in drug contentmeasurement becausemethanol
was known as universal solvent that had ability to extract whole
mefenamic acid that covered inside globul (Cole, 2003).
Results of SNEDDS drug content had good precision be-
cause their RSD (Table 3) > 7.3 % so % drug content 13 formu-
las can be continued at DX®10 analysis (AOAC Intenational,
2012). Result of % drug content SNEDDS mefenamic acid
(Table 3) showed that run 13 (93.04 %) has the highest % drug
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Figure 1. Diagram of ternary phase capryol90, polysornate80 and PEG400
Figure 2. The image of SNEDDS mefenamic acid
content while run 12 (79.80 %) was the lowest and did not
meet the requirement because exceeded the minimum ICH
limit (2005) (80 - 120%). This causes the therapeutic did not
to be achieved thepain relief eect (Abraham et al., 2013).
The SNEDDS component was thought to play role in inu-
encing the drug content, therefore the analysis of the eect
of SNEDDS components on drug content using DX®10 was
discussed further.
Special quartic was chosen by DX as analytical model be-
cause p-value lack of t of this model was most unsignicant
(0.3120 > 0.10). The combination of A2BC, AB, ABC2 had
signicant eect on % drug content because the factor had p-
value < 0.05. The inuence of A2BC > AB >ABC2 because the
relationship bipolysorbate p-value and the factor eect was op-
posite, so lower p-value make the greater factor eect. DX®10
Analysis formed 3 equations which express the inuence of
each component to % drug content (Stat-ease, 2016).
Y = 88,09 A + 83,98 B + 86,5 C - 26 AB + 3,34 AC + 18,38
BC + 879,82 A2 BC – 194,16 AB2 C – 511,45 ABC2
Description:
Y = % drug content
A = capryol-90 proportion
B = polysorbate-80 proportion
C = PEG-400 proportion
Florentia (2013) reported that positive coecient A2BC
value give synergic eect, while the negative AB dan ABC2
value showed antagonist eect to the response. More double
combination of capryol-90 (A2BC) can increase % drug content
because hydrophobic property of capryol-90 causesmefenamic
acid easier to dissolve. AB and ABC2 factors decrease % drug
content because the non-polar carbon chain of polysorbate-
80 and PEG-400 caused capryol-90 to break their bond with
mefenamic acid, hence the solubility of mefenamic acid is
decreased.
3.6 Emulsication Time and Precipitation Observation
Self-emulsication ability become the main point in SNEDDS
evaluation because bioavailability and oral absorption eciency
of practically insoluble drug can be increased by self-emulsication
process that generate ne dispersion and micellar to avoid drug
precipitation and recrystallization (Pouton, 1997). The For-
mula indicated to have good self-nanoemulsication ability if
emulsion components (capryol-90, polysorbate-80, and PEG-
400) can completely disperse in short time when mixed with
aqueous phase with a little help from low agitationof peristaltic
activity (Porter et al., 2007; Parmar et al., 2011).
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Figure 3. The formation of SNEDDS mefenamic acid globul during self-nanoemulsication
3.7 Observation of Physical Stability
Physical stability was carried out to determine the maximum
storage duration which can lead to the separation of emul-
sion (creaming or cracking) phases. The test results show if
SNEDDS mefenamic acid had good stability because for 3
cycles heating cooling does not show phase separation, viscos-
ity change and SNEDDS color. This proves the statement
of (Hintzen et al., 2014) and (Weerapol et al., 2014) if the
SNEDDS dosage form has good physicochemical stability.
This was because the mefenamic acid dissolving well in the
SNEDDS component has improved the stability of the prepa-
ration (Parmar et al., 2011).
Capryol-90 which has maximum solubility to mefenamic
acid and the use of polysorbate-80 30-60% (w/w) can dissolve
more mefenamic acid so can minimize the mefenamic acid
precipitation. PEG-400 as co-surfactant according to Jaiswal
et al. (2014) can dissolve hydrophilic surfaces and drugs in the
oil phase so can help maintain SNEDDS stability.
3.8 Response of the SNEDDS Mefenamic Acid Optimum
Formula
Run 6 of formulas were selected as representatives of 13 for-
mulas because they have SNEDDS component proportions
that resemble the proportion of the optimum formula. The
drug content response of the optimum formula was dierent
enough while the viscosity, emulsication time, pH SNEDDS
(5.5) depends on capryol-90, polysorbate-80, and PEG400
compositions so that the dierence in measurement results of
the optimum formula and formula was not much dierent. The
physical stability of optimum formula SNEDDS was physically
stable because it did not show separating emulsion phase or
the deposition of mefenamic acid during the 3 heating cooling
cycles test. However, the result of stability test determination
showed that there was degradation of mefenamic acid from 8.2
ppm to 7.0 ppm. Mefenamic acid degradation is estimated to
occur due to increasing temperature extremely in the heating
cooling process. (Martin and Bustamante, 1993) describes if
the rate of degradation reaction can increase 2-3 times every
10°C temperature increase due to increased kinetic energy of
the molecule resulting in the decomposition of the molecular
complex of mefenamic acid.
3.9 Statistical Analysis ofDrugContent, andEmulsication
Time of Optimum Formula SNEDDS
Precision of 3 responses test method has suitable precision
because RSD (4,819%) <7.3%. The test results of the dierence
of one sample t-test with α 0.05 indicate if the drug content,
emulsication time, and viscosity of predicted value DX®10
diered signicantly (p-value <0.05 on the experimental results
(Table 4). This dierence was expected to occur because the
DX®10 program did not relevant to the eects of variations in
test conditions (such as environmental conditions, testing tools,
human error) in predicting response (Stat-ease, 2016).
3.10 In Vitro Dissolution
Dissolution tests were performed to determine the process
of release of mefenamic acid from SNEDDS dosage form,
generic caplets, and pure mefenamic acid capsules. Dissolu-
tion becomes the most important characteristic in testing the
mefenamic acid SNEDDS response because the faster the dis-
solution is, the more likely it is to minimize the elimination
caused by the rst pass eect. This may increase the amount of
absorbed mefenamic acid so that the analgesic eects of mefe-
namic acid can be felt only by the low dose of mefenamic acid.
The rapid increase in the release of cumulative mefenamic acid
of SNEDDS in minute-5 (Figure 4) occurred due to the rapid
formation of spontaneous nanoemulsion which increased the
solubility of mefenamic acid in water.
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Table 3. Response test result of 13 formulas SNEDDS mefenamic acid
Formula
Average
RSD
Average
RSDDrug Content Emulsication Time
(%) ± SD (second) ±SD
Run 1 85.01 ± 0.87 3.137 165.58 ± 0,72 0.434
Run 2 79.80 ± 0.59 1.018 900 ± 0 0
Run 3 86.84 ± 2.72 3.364 900 ± 0 0
Run 4 82.29 ± 2.48 4.944 900 ± 0 0
Run 5 83.08 ± 0.06 0.742 166.52 ± 1,35 0.81
Run 6 90.10 ± 0.70 5.509 457.51 ± 3,64 0.795
Run 7 88.39 ± 2.91 2.964 900 ± 0 0
Run 8 83.06 ± 3.45 4.154 900± 0 0
Run 9 87.49 ± 2.94 0.076 720.35 ± 2,40 0.333
Run 10 85.65 ± 4.72 3.296 732.75 ± 0,25 0.034
Run 11 89.46 ± 4.42 3.01 900 ± 0 0
Run 12 89.04 ± 1.04 1.169 900 ± 0 0
Run 13 93.04 ± 2.76 0.773 900 ± 0 0
Explanation: Run 5, 10 and 11 is replicate formula of Run 1, 9, and 3
Table 4. The results of the statistical analysis of predictive value of DX®10 of formula SNEDDS
Evaluation
DX®10 Experiment
p-valuePrediction (N=3) ± SD
Drug content (%) 89,512 102,820 ± 4,950 0,043
Emulsication Time (second) 428,933 421,015 ± 1,290 0,009
Viscosity (mm2/s 30ºC) 0,868 0,927 ± 0,017 0,026
Figure 4. The dissolution prole of SNEDDS mefenamic acid
The result of ANOVA% release of mefenamic acid and
DE60 from SNEDDS, caplet, and pure capsule showed signi-
cant dissolution (sig. <0.05). Post hoc LSD and Tukey in the
minute-10 (when% release 100%) and theminute-60 (nal stage
of dissolution) showed if%release bipolysorbate dosage form
also dierent signicantly (sig. <0.05). The DE60 SNEDDS
value was greater than pure capsules and commercial generic
caplets because the % release SNEDDS has been able to reach
109% at the minute-10. The ANOVA results and the dis-
solution graph (Figure 4) show that SNEDDS able to im-
prove the mefenamic acid dissolution signicantly. Kinetics of
mefenamic acid release from SNEDDS, caplet, or pure cap-
sule follows order 0 so that the rate of release of mefenamic
acid was not aected by concentration but by the solubility of
mefenamic acid to dissolution media (Martin and Bustamante,
1993). This was because the diculty in dissolving mefenamic
acid in the SIF medium (0.01 mg/mL) became strength the
stagnant diusion layer to eliminate the sink conditions during
the test. The KH value of the Higuchi kinetics model ≥ 1 illus-
trates the release of mefenamic acid from SNEDDS, generic
capsules and caplets also undergoing diusion processes (Gur-
soy and Benita, 2004). The mefenamic acid nanoemulsion
formation increases solubility in the SIF so that SNEDDS
could narrow the distance of the stagnant diusion layer thus
accelerating the dissolution of mefenamic acid.
The super-case-II transport (n> 1) model was inuential if
the release of mefenamic acid was done by reducing the poly-
mer chains in the SNEDDS (capryol-90, polysorbate-80 and
PEG-400) preparations and caplets (Costa and Lobo, 2001;
Lawrence and Rees, 2012). Dissolved mefenamic acid in ei-
ther a non-polar solvent (capryol-90) after passing through a
stagnant diusion layer could immediately reduced the bond
to the capryol-90 polymer followed by the breaking of the
polysorbate-80 and PEG-400 polymers to form the SIF emul-
sion so that there became a reduction of the polymer chain,
polysorbate-80, and PEG-400 from micro to nano-size.
The value of pure mefenamic acid capsule (0.1798) illus-
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Figure 5. Physical properties of SNEDDS mefenamic acid
trates if the release of mefenamic acid only follow Fick diusion
process (Costa and Lobo, 2001). This was because the pure
capsule preparations were not added to the polymer so that the
release only relied on the transfer of mefenamic acid through
the homogeneous membrane which was strongly inuenced
by the sink conditions (Martin and Bustamante, 1993).
3.11 Diameter Analysis, PDI, and Potential Zeta of SNEDDS
Droplet
Measurement of diameter of droplets on PSA aims to deter-
mine the size of nanoemulsion droplets when in the diges-
tive tract uid. Average diameter of the established SNEDDS
droplets was 241.9 nm with good size uniformity (PDI (18%)
<20%) (Figure 5).
SNEDDS zeta potential in -16.5 mV indicates if nanoemul-
sion dispersion tends to have slow coagulated and occulated
(Martin et al., 1995). This was because a potential zeta value of
± 25 mV has been able to form a stable nanoparticle through
themechanism of forming a protective layer around the droplet
from the pull of bonding together the dispersing medium to
avoid the unication of SNEDDS droplet. The negative droplet
surface SNEDDS droplets was due to the negative electron oxy-
gen (O) atom in the mefenamic acid group, polysorbate-80,
PEG-400 created an electron cloud on the emulsion molecule.
4. CONCLUSIONS
The proportion of capryol-90, polysorbate-80, and PEG-400-
forming nanoemulsion regions of SNEDDS mefenamic acid
were 20-40%, 20-40%, and 40-60%, respectively. The pro-
portion of capryol-90, polysorbate-80, and PEG-400 in opti-
mal formula of SNEDDS mefenamic acid was (20; 31.62;
48.38)%. An optimal formula SNEDDS showed the drug
contentof (105.210 ± 4.425)%, the commercial generic caplet
(0.917 ± 0.094)%, and mefenamic acid powder capsule (10.446
± 0.333)%. An optimal formula revealed that the SNEDDS
could signicantly increase mefenamic acid dissolution of pH
7.4 (ileum uid). The physical properties of mefenamic acid
SNEDDS successfully formed an uniformity droplet size (PDI
0.18) with mean size 241.9 nm and the surface charge had a
value of -16.5 mV respectively.
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